{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:29:52Z","timestamp":1776893392901,"version":"3.51.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02834-9","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T03:26:45Z","timestamp":1713151605000},"page":"2267-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor\u00a0VIII Replacement in Severe Hemophilia\u00a0A"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03370913","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Johannes","family":"Oldenburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Chambost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Hatswell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareth","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"issue":"suppl 6","key":"2834_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"8","key":"2834_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540\u20136.","journal-title":"Ann Intern Med"},{"issue":"24","key":"2834_CR3","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.3390\/jcm10245959","volume":"10","author":"G Kenet","year":"2021","unstructured":"Kenet G, Chen YC, Lowe G, et al. Real-world rates of bleeding, factor\u00a0VIII use, and quality of life in individuals with severe haemophilia\u00a0A receiving prophylaxis in a prospective, noninterventional study. J Clin Med. 2021;10(24):5959.","journal-title":"J Clin Med"},{"issue":"11","key":"2834_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia\u00a0A. N Engl J Med. 2022;386(11):1013\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"2834_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia\u00a0A. N Engl J Med. 2020;382(1):29\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"2834_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-019-1002-z","volume":"14","author":"CMW Gaasterland","year":"2019","unstructured":"Gaasterland CMW, van der Weide MCJ, du Prie-Olthof MJ, et al. The patient\u2019s view on rare disease trial design: a qualitative study. Orphanet J Rare Dis. 2019;14(1):31.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2834_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Kim HJ, Lonjon G, Zhu Y, AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7(1):16.","journal-title":"Ann Transl Med"},{"issue":"3","key":"2834_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"2834_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","volume":"2022","author":"AC Nathwani","year":"2022","unstructured":"Nathwani AC. Gene therapy for hemophilia. Hematol Am Soc Hematol Educ Program. 2022;2022(1):569\u201378.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"2834_CR10","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","volume":"106","author":"A Tiede","year":"2021","unstructured":"Tiede A, Abdul Karim F, Jim\u00e9nez-Yuste V, et al. Factor\u00a0VIII activity and bleeding risk during prophylaxis for severe hemophilia\u00a0A: a population pharmacokinetic model. Haematologica. 2021;106(7):1902\u20139.","journal-title":"Haematologica"},{"issue":"13","key":"2834_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","volume":"127","author":"N Uchida","year":"2016","unstructured":"Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase\u00a01 study of ACE910, a novel factor\u00a0VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633\u201341.","journal-title":"Blood"},{"issue":"4","key":"2834_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/hae.14818","volume":"29","author":"J Astermark","year":"2023","unstructured":"Astermark J, Buckner TW, Frenzel L, et al. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia\u00a0A: comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. 2023;29(4):1087\u201394.","journal-title":"Haemophilia"},{"issue":"8","key":"2834_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia\u00a0A. N Engl J Med. 2023;388(8):694\u2013705.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02834-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02834-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02834-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T13:22:12Z","timestamp":1716902532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02834-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2834"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02834-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"11 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Johannes Oldenburg received reimbursement for attending symposia\/congresses, honoraria for speaking or consulting, or funds for research from Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and Sobi. Herve Chambost received consulting payments from BioMarin Pharmaceutical Inc., CSL Behring, LFB, Novo Nordisk, Pfizer, Roche Chugai, and Sobi; received speaker fees from BioMarin Pharmaceutical Inc., CSL Behring, Pfizer, Roche, and Sobi; and received travel support from BioMarin Pharmaceutical Inc., CSL Behring, Novo Nordisk, Octapharma, Roche, and Sobi. Anthony J. Hatswell is an employee of Delta Hat Ltd, who were contracted by BioMarin Pharmaceutical Inc. to contribute to these analyses. Hai Liu, Xinqun Yang, Tara M. Robinson, and David Hinds are employees and stockholders of BioMarin Pharmaceutical Inc. Charles Hawes and Sandra Santos are employees and stockholders of BioMarin UK Ltd. Vanessa Newman was an employee of BioMarin Pharmaceutical Inc., at the time of study and is now the current owner of Garthorne Medical & Clinical Limited. Xiaojun You was an employee of BioMarin Pharmaceutical Inc., at the time of study and is a current employee of Regeneron. Margareth Ozelo reports consulting fees from Bayer, BioMarin Pharmaceutical Inc., Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda; research grants from Pfizer, Roche, and Takeda; participation as a clinical trial investigator for BioMarin Pharmaceutical Inc., Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda; speaker honoraria from Bayer, BioMarin Pharmaceutical Inc., Novo Nordisk, Roche, and Takeda; travel support from Novo Nordisk, Roche, and Takeda; and participation in grant reviewing for Grifols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This manuscript provides a post\u00a0hoc analysis of previously conducted studies and does not include the addition of new studies with human participants or animal subjects. As previously reported, the 270-902 and GENEr8-1 protocols were approved by the institutional review boards or independent ethics committees of all participating sites, and all participants provided written informed consent. Both trials were performed in accordance with the ethical principles set forth by the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}